Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease
A special issue of Journal of Clinical Medicine (ISSN 2077-0383).
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 28353
Special Issue Editors
Interests: biomarkers; cirrhosis; hepatitis B virus; hepatocellular carcinoma; hepatitis D virus; inflammatory bowel disease; liver fibrosis; non-alcoholic fatty liver disease
Special Issues, Collections and Topics in MDPI journals
Interests: inflammatory bowel diseases; Crohn’s disease; ulcerative colitis; celiac disease; microbiota; eosinophilic esophagitis; irritable bowel syndrome; biologics; diverticular disease; Helicobacter pylori
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis, both of which are characterized by chronic and uncontrolled inflammation of the intestinal tract. Despite the fact that pathogenesis remains poorly understood, IBD is known to result from the interaction between genetic and environmental factors which influence immune responses to components of the intestinal microbiome. From an epidemiological point of view, the global burden of IBD continues to increase worldwide. Considering the strongly debilitating clinical course of the disease that causes serious implications for the patients, IBD has recently become a serious challenge in medical science.
New biologics (anti-integrin, anti-IL12-23) and small molecules (anti-Janus kinase) are increasingly entering in the market, but it is not clear if these drugs are able to reduce the number of surgical resections and to change the natural history of the disease. In particular, since the therapeutic choices are always wider, the main focus of the research will be to find predictors of the therapeutic response (pattern of interleukins, markers of bowel permeability) to help clinicians to choose between drugs with different mechanisms of action and to determine when surgery should be used instead of drugs.
This Special Issue aims to present and discuss novel immunological concepts applied in the treatment and management of patients with IBD.
Dr. Gian Paolo Caviglia
Dr. Davide Giuseppe Ribaldone
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- biological therapy
- non-invasive biomarkers
- Crohn’s disease
- ulcerative colitis
- intestinal permeability
- inflammation